Liquidia Tech Rg

Liquidia Corp. develops inhaled treprostinil (YUTREPIA) for PAH/PH‑ILD, with Remodulin and investigational L606. Licensed partnership with Pharmosa; U.S. manufacturing hub in Morrisville, NC.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 170
HQ: Morrisville

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
LQDA	Liquidia Tech Rg Cap: 3.1B	EQUITY	NMS	USD	US53635D2027	Active	📈